Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant docetaxel before radical prostatectomy in high-risk localized prostate cancer
2009-014491-21Phase 2Terminated
- Sponsor
- Cambridge University Hospitals NHS Foundation Trust
- Start
- Oct 2009
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of docetaxel in prostate cancer (PCa), sponsored by Cambridge University Hospitals NHS Foundation Trust. Primary endpoint: Biological, pathological, and imaging change induced by docetaxel. Started Oct 2009; status: terminated.
02
Drugs
docetaxel
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on 2009-014491-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-014491-21.